[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exercise-tolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exercise-tolerance":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":37,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100603978","early-exercise-based-rehabilitation-in-patients-hospitalized-for-acute-pulmonary-embolism-100603978",false,"NCT07143539","Early Exercise-Based Rehabilitation in Patients Hospitalized for Acute Pulmonary Embolism","Early Exercise-based Rehabilitation in High-risk Patients Hospitalized for Acute Pulmonary Embolism: a Pragmatic Multicenter Randomized Partially Blinded Superiority Trial","RehabPE","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Hospitalization for objectively confirmed acute symptomatic PE, defined as intraluminal filling defect of a segmental or more proximal pulmonary artery on computed tomography pulmonary angiography (CTPA) or a high-probability ventilation-perfusion scintigraphy, and admission within the past 7 days\n3. Increased risk for post-PE syndrome, defined as simplified Pulmonary Embolism Severity Index (sPESI) ≥1 point at the time of admission\n4. Written informed consent\n\nExclusion Criteria:\n\n1. Contraindication to EBR (known unstable cardiac conditions like angina pectoris, severe valvular heart disease, or severe resting pulmonary hypertension)\n2. Medical condition that clearly precludes participation in EBR (e.g., inability to walk, unstable joints, severe neurological impairment)\n3. Recently completed (i.e., \\\u003C6 months), ongoing, or planned in- or outpatient EBR, or planned supervised outpatient physiotherapy for any indication\n4. Planned hospitalization during follow-up (e.g., elective surgery or inpatient chemotherapy)\n5. Contraindication to anticoagulation\n6. Life expectancy \\\u003C1 year based on the treating physician's clinical judgement\n7. Known pregnancy\n8. Inability to speak German or French\n9. Participation in another study that prohibits concurrent participation in RehabPE\n10. Unable to provide informed consent (e.g., due to dementia)\n11. Unwilling to provide informed consent\n12. Prior enrollment in this study","ALL","18 Years",{"count":20,"type":21},160,"ESTIMATED","INTERVENTIONAL",[24],"NA","Up to half of patients with pulmonary embolism (PE) suffer from impaired quality of life, reduced physical capacity, and symptoms like shortness of breath even three months after diagnosis, despite standard treatment with anticoagulation (blood thinners). The randomized RehabPE trial investigates whether an early, structured rehabilitation program with physical training and patient education can prevent such long-term effects.\n\nThe study includes hospitalized patients with acute symptomatic PE who are at increased risk of impaired quality of life three months after diagnosis. After informed consent, patients are randomly assigned to one of two groups: one receives an early 6-8-week, center-based rehabilitation program; the other receives standard follow-up care without rehabilitation. The intervention group completes 16-18 outpatient sessions of endurance and strength training, along with two education sessions covering the condition, treatment, and symptom management.\n\nOver 180 days, changes in quality of life, physical exercise capacity, breathlessness, and psychological symptoms, and the time to return to work \u002F usual daily activities will be monitored and compared between groups.",[27,28,29,30,31,32,33,34,35,36],"Venous Thromboembolism (VTE)","Exercise Therapy","Quality of Life (QOL)","Anxiety Depression","Humans","Exercise Tolerance","Rehabilitation Exercise","Dyspnea","Functional Status","Pulmonary Embolism (Diagnosis)",[38,39,40,41,42,43,44,45,46],"pulmonary embolism","deep vein thrombosis","excercise-based rehabilitation","post-PE syndrome","health-related quality of life","anxiety","depression","dyspnea","impact of early excercise-based rehabilitation","RECRUITING","2026-06-11",{"date":50,"type":51},"2026-06-12","ACTUAL",{"date":53,"type":51},"2025-12-17",{"date":55,"type":21},"2028-06",{"name":57,"class":58},"Insel Gruppe AG, University Hospital Bern","OTHER",6,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":17,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":71,"briefSummary":72,"conditions":73,"keywords":77,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100604054","nicotinamide-mononucleotide-supplementation-for-exercise-tolerance-improvement-in-healthy-older-adults-100604054","NCT07144527","Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults","Inclusion Criteria:\n\n* Adults aged 60 to 80 years, of any sex\n* Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study\n* Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing\n* Montreal Cognitive Assessment (MoCA) score of 26 or higher\n* Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation\n* Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling\n* Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications\n* Ability to attend at least four in-person laboratory visits in Beverly Hills, California\n* Non-smoker for at least 12 months\n* Able to provide informed consent and comply with study procedures\n* Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study\n\nExclusion Criteria:\n\n* Severe cardiovascular disease (e.g., recent myocardial infarction \\\u003C6 months, unstable angina, uncontrolled hypertension \\>160\u002F100 mmHg)\n* Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)\n* Significant neurological impairments that hinder comprehension of instructions or participation in exercise\n* Terminal illness or conditions limiting life expectancy or ability to complete the study\n* Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions\n* Significant orthopedic limitations or injuries that prevent safe exercise participation\n* Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks\n* Anticipated or current alcohol consumption \\>2 drinks per week, or unwillingness to abstain from alcohol during the study\n* Current substance abuse affecting study participation or adherence\n* Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives\n* Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion\n* Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results",true,"60 Years","80 Years",{"count":70,"type":21},40,[24],"This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.\n\nThe primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.\n\nEGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.",[74,75,32,76],"Aging","Frailty","Healthy Male and Female Subjects",[78,79,32,74,80,81,82,83,84,85,86,87,88],"Nicotinamide Mononucleotide","NAD+ Metabolism","Older Adults","Betaine","Hydrogen Peroxide (low-dose, dietary)","High Intensity Interval Training","VO2peak","Lactate Threshold","Critical Power","Anaerobic Work Capacity","Healthy Volunteers","2026-02-19",{"date":91,"type":51},"2026-02-20",{"date":93,"type":21},"2026-02-21",{"date":95,"type":21},"2027-01-01",{"name":97,"class":58},"Scott Silveira",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":66,"sex":17,"minAge":18,"maxAge":68,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":124,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100552680","m4c-nutraceutical-intervention-human-health-effects-pilot-100552680","NCT06476236","M4C Nutraceutical Intervention Human Health Effects Pilot","M4C Pilot","Inclusion Criteria:\n\n* Healthy adults\n\nExclusion Criteria:\n\n* amputation\n* blood clotting disorder\n* metal implants or implanted electrical device(s)\n* known acute or chronic illness; gastrointestinal, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension\n* inability to fast i.e. low blood sugar\n* pregnant or may be pregnant during the course of the study\n* amino acid metabolizing disorder i.e. phenylketonuria\n* severe edema\n* did not pass screening criteria as determined by MRI facility\n* allergies\u002Fintolerance to any nutraceutical ingredients: amino acids, vitamins, minerals, tapioca starch, sunflower lecithin, stevia, limes or fatty acids like docosahexaenoic acid",{"count":107,"type":21},20,[24],"This 3 month pilot study will be an unblinded, convenience sampling, nutraceutical intervention trial. Twenty fasted subjects will undergo a baseline health assessment via a questionnaire, baseline clinical chemistries, blood lipids, dexa and impedence testing (to identify bone mineral density and body muscle\u002Ffat\u002Fwater composition), and metabolite\u002Fnovel biomarker testing through whole capillary blood, saliva, and urine collections. Assessments will be repeated every month (3 times after initial assessment) to cover a 3 month period. All measurements from each visit will be compared with baseline using paired t-tests or Chi square testing depending on variable. Power analyses are not included due to the pilot nature of the study. This pilot study will provide the necessary variability estimates for future trials.",[111,112,113,114,115,32,116,117,118,119,120,121,122,123],"General Health and Wellness","Energy and Vitality","Cognitive Function and Mental Health","Weight Management","Digestive Health","Cardiovascular Health","Bone and Joint Health","Skin, Hair, and Nail Health","Immune Support","Sports Performance and Recovery","Sleep and Relaxation","Obesity","Anti Inflammatory",[111,112,113,114,115,32,116,117,118,119,120,125,122,126],"Sleep and relaxation","anti inflammatory","NOT_YET_RECRUITING","2024-06-24",{"date":130,"type":51},"2024-06-26",{"date":132,"type":21},"2024-06-17",{"date":134,"type":21},"2025-06-17",{"name":136,"class":58},"Concordia University Wisconsin"]